Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBT (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBT for 4 consecutive years, with -$54.7 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 30.43% to -$54.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$239.3 million, a 51.15% decrease, with the full-year FY2024 number at -$232.9 million, down 32.23% from a year prior.
  • EBT was -$54.7 million for Q3 2025 at Centessa Pharmaceuticals, down from -$49.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$24.7 million in Q1 2025 to a low of -$110.3 million in Q4 2024.
  • A 4-year average of -$50.3 million and a median of -$48.9 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 208.97% in 2024, then surged 34.15% in 2025.
  • Centessa Pharmaceuticals' EBT stood at -$43.8 million in 2022, then increased by 18.58% to -$35.7 million in 2023, then tumbled by 208.97% to -$110.3 million in 2024, then soared by 50.38% to -$54.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EBT are -$54.7 million (Q3 2025), -$49.6 million (Q2 2025), and -$24.7 million (Q1 2025).